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The polysaccharide capsule is the most important viru-
lence factor of Streptococcus pneumoniae, however it is
neither a requirement for persistent carriage nor for
transmission. It has been postulated that reduced or
complete lack of capsule expression facilitates coloniza-
tion of the nasopharynx as a result of enhanced binding
to epithelial cells.1 On the other hand, the large invest-
ment of energy in the synthesis of a polysaccharide cap-
sule protect the pneumococci against complement
mediated killing.2 Furthermore, a capsule might prevent
agglutination in a mucus rich environment avoiding
clearance from the nasopharyngeal cavity.3
An important group of pneumococci is serologically
nontypeable (NT) due to the lack of a capsule, therefore
called non-encapsulated Streptococcus pneumoniae
(NESp). They are divided in 2 groups: group I, which
contains a conventional but defective cps locus as a con-
sequence of different types of mutations causing capsule
gene inactivation and group II, which completely lacks a
cps locus.4 The latter group consists of 3 ‘null capsule
clades’ (NCC), classiﬁed based on the presence of 3 genes
pspK (or nspA), aliC (or aliB-like ORF1) and aliD (or
aliB-like ORF2): NCC1 (pspKC, aliC¡, aliD¡), NCC2
(pspK¡, aliCC, aliDC), NCC3 (pspK¡, aliC¡, aliDC). The
pspK, aliC and aliD genes have replaced the capsule
locus, and recombination of ﬂanking homologous genes
(dexB and aliA) has the potential to transfer this gene
cluster between encapsulated and non-encapsulated
strains. It has been shown that group II NESp can colo-
nize mouse nasopharynges as well as capsulated pneu-
mococci, which implies that they have been able to
compensate for the lack of a capsule enabling persistent
carriage.4
The current pneumococcal vaccines are made of puri-
ﬁed conjugated (10 or 13 valent) or non-conjugated (23
valent) polysaccharide capsules, which evidently do not
protect against NESp. Vaccination with a limited num-
ber of serotypes leads to an increased pressure on a spe-
ciﬁc subset of pneumococci that opens an environmental
niche that NESp strains are able to exploit.5 This might
explain why an increase in NESp prevalence has been
observed following the introduction of pneumococcal
conjugate vaccines.6 Asymptomatic carriage rates of
NESp have been measured, ranging from 4% to 19%.7, 8
Generally, NESp cause mainly non-invasive pneumococ-
cal diseases such as otitis media and infectious conjuncti-
vitis. In rare cases, infection with NESp can also lead to
invasive pneumococcal disease, although mainly in
immunodeﬁcient patients. Nevertheless, the total num-
ber of clinical cases caused by NESp might be underesti-
mated since serotyping is not routinely performed.5
A potentially more serious concern is the role of NESp
in the spread of antibiotic resistance and virulence genes.
The pneumococcus exploits different mechanisms to
mediate horizontal gene transfer and recombination,
including transformation, the use of mobile elements
and transducing phages.9 Despite the great advantages of
having a capsule, providing resistance to clearance dur-
ing colonization, it strongly hampers DNA uptake limit-
ing the capability of transformation-mediated
adaptation. In vitro studies have shown that capsule-neg-
ative mutants acquire genes through recombination at a
higher frequency than the isogenic encapsulated strains.1,
10 In the largest pneumococcal sequencing study thus far,
with more than 3000 isolates, it was found that NESp
showed the highest frequencies of receipt and donation
of recombined DNA fragments, conﬁrming that they are
a potential major reservoir of genetic diversity for the
wider population. The model proposed by Andam and
Hanage explains how frequent loss and subsequent gain
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of capsule loci contribute to the observed variation in
recombination rates and antibiotic resistance among
pneumococcal lineages.9 It is proposed to start with ran-
dom single nucleotide polymorphisms, deletions or
transposon insertions leading to a group I NESp with
increased capabilities of acquiring exogenous DNA,
including virulence or antibiotic resistance genes. How-
ever, the sudden loss of capsule will make them more
vulnerable for clearance, which is therefore likely a tran-
sient condition. The strain will either quickly regain its
original or another capsule, or acquire the pspK, aliC
and/or aliD genes to become a group II NESp, which is
much better adapted than group I NESp allowing pro-
longed uptake of exogenous DNA. Subsequently, these
group II NESp strains might at some point switch to an
encapsulated state again. This cycle of encapsulation and
un-encapsulation is thought to play an important role in
the pneumococcal population dynamics and the spread
of antibiotic resistance and virulence genes. This might
explains why a signiﬁcant proportion of NESp is resis-
tant against one or multiple classes of antibiotics, as
recently reviewed by.5
Jang et al. studied one of the most important proteins
involved in capsule-independent persistence of carriage,
the pneumococcal surface protein Korea (PspK), as
potential vaccine antigen.11 The pspK gene is widely
spread in NESp group II strains in Asia.12 Mature PspK,
an LPxTG-anchored protein, consists of an undeﬁned
domain (UD), an R3 domain, showing homology with
the R1 domain of PspC and both containing a-helical
structures and a more conserved part containing
stretches of 7 amino acid repeats. Deletion of the pspK
gene led to reduced adherence but increased invasion
into lung epithelial cells. PspK-mediated interaction with
epithelial cells was dependent on a speciﬁc interaction
between the R3 domain and Annexin-2, a membrane
protein involved in actin-driven cellular uptake. Jang
et al. showed furthermore that vaccination with R3
induced protection, showing the strongest effects mea-
sured after intranasal immunization.11 Despite the vari-
ability of PspK, antibodies raised against this protein
cross-reacted with 79% of the encapsulated strains not
containing PspK. This cross-reactivity is likely due to
recognition of domains of distantly related proteins,
such as PspC and PspA, therefore much higher cross-
reactivity is expected with PspK containing NESp.
Although the results are suggestive of an antibody-medi-
ated mechanism of protection, it cannot be excluded that
Th17 responses are induced, as has been shown to be
essential for PspA-mediated protection.13
In conclusion, the study of Jang et al. shows the potential
of PspK as vaccinate candidate,11 thereby also conﬁrming
earlier work from Keller et al. (2015).14 Whether the other
group II NESp-speciﬁc proteins AliC and AliD are protec-
tive antigens remains to be studied. It is tempting to specu-
late that vaccination with proteins essential to compensate
for the lack of a capsule such as PspK, AliC and AliD will
result in strong reduction of colonization disrupting the
chain of horizontal gene transfer and recombination. This
might ultimately lead to the prevention of the emergence of
capsule switching and antibiotic resistance.
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